Pharmacy Benefit Manager

Armed with predictive analytics, PBMs push adherence as a stand-in for outcomes

Armed with predictive analytics, PBMs push adherence as a stand-in for outcomes

By

Pharmacy benefit managers are increasingly measuring a patient's outcome in the context of adherence.

Five things for pharma marketers to know: Friday, October 27, 2017

Five things for pharma marketers to know: Friday, October 27, 2017

By

CVS Health reportedly in talks to acquire Aetna; Amazon acquires wholesale pharmacy licenses; Merck says June cyberattack disrupted global operations

Five things for pharma marketers to know: Friday, September 22, 2017

Five things for pharma marketers to know: Friday, September 22, 2017

By

Express Scripts' Miller says new models needed to pay for CAR-T; FDA warns about Intercept drug deaths; CVS puts limits on opioid scripts

Five things for pharma marketers to know: Wednesday, August 9, 2017

Five things for pharma marketers to know: Wednesday, August 9, 2017

By

The FDA on pace for record generic drug approvals; CVS Health CEO doubts Amazon's entrance to pharmacy market; Sanofi to develop cancer immunotherapy

Five things for pharma marketers to know: Tuesday, April 25, 2017

Five things for pharma marketers to know: Tuesday, April 25, 2017

By

Sanofi sues Mylan over anticompetitive practices; Anthem to drop Express Scripts; GSK chief digital officer says advertisers should focus on fewer publishers

Five things for pharma marketers to know: Tuesday, April 4, 2017

Five things for pharma marketers to know: Tuesday, April 4, 2017

By

Mylan allegedly increased EpiPen list price to appease PBMs; 20% of patients misdiagnosed by primary-care doctor: study; Mallinckrodt settles DEA probe

Five things for pharma marketers to know: Tuesday, March 21, 2017

Five things for pharma marketers to know: Tuesday, March 21, 2017

By

Eli Lilly claims it only realizes small percentage of list price increases; PBMs become latest target in pricing backlash; AHCA revised

Five things for pharma marketers to know: Wednesday, January 11, 2017

Five things for pharma marketers to know: Wednesday, January 11, 2017

By

The FDA accepts Keytruda combo for review; Valeant offloads Dendreon and skincare brands; pharmacies feeling the squeeze from Express Scripts

Five things for pharma marketers to know: Tuesday, November 8, 2016

Five things for pharma marketers to know: Tuesday, November 8, 2016

By

FDA solicits public comment to study online character space limit; Biogen's Spinraza shows positive results in SMA study; Valeant cuts earnings forecast

Five things for pharma marketers to know: Wednesday, August 31, 2016

Five things for pharma marketers to know: Wednesday, August 31, 2016

By

The FDA approves an Enbrel biosimilar; Express Scripts to launch program to reduce diabetes costs; a GSK vaccine beats sales forecasts

Five things for pharma marketers to know: Friday, March 18, 2016

Five things for pharma marketers to know: Friday, March 18, 2016

By

OptumRx partners with Walgreens Boots Alliance; Turing's former lawyer said Daraprim price hike was unjustified; the White House names moonshot leader

With PCSK9s, payers say, 'Let the market decide'

With PCSK9s, payers say, 'Let the market decide'

By

It's possible that payers won't prove the wild card in the PCSK9 derby. Instead, physician preference may do more to shape the market and maybe even force payers' hands.

Five things for pharma marketers to know: Friday, December 11, 2015

Five things for pharma marketers to know: Friday, December 11, 2015

By

UnitedHealth gives Praluent preferred status on its formularies; Stat News examines the first DTC drug ad; Britain to cover Entresto

Market Access: Looking Back, Looking Ahead

Market Access: Looking Back, Looking Ahead

Securing market access has become significantly more challenging for pharma marketers.

Five things for pharma marketers to know: Monday, November 16, 2015

Five things for pharma marketers to know: Monday, November 16, 2015

By

PBMs crack down on specialty pharmacies; Merck's cholesterol drug soldiers on; rare-disease drug nabs approval

Express Scripts to cover Repatha and Praluent

Express Scripts to cover Repatha and Praluent

By

The pharmacy benefit manager included both PCSK9 inhibitors on its national formulary. Spending on the drugs is estimated to reach $750 million in 2016.

Price fixing: PBMs push for lower prices of PCSK9 inhibitors

Price fixing: PBMs push for lower prices of PCSK9 inhibitors

By

Now that the first two PCSK9 inhibitors have been given the thumbs-up by the FDA, the payer community finds itself in a situation comparable to the one it faced upon the arrival of transformative hep.-C drugs: What are they prepared to pay—and which drugs will get the formulary nod? Jaimy Lee assesses the fluid market dynamics

PCSK9 inhibitors necessitate an update to heart guidelines, CVS Health says

The pharmacy benefit manager said that the introduction of new treatments and clinical evidence on statins demands a rethink to ACC/AHA guidelines

Five things for pharma marketers to know: Friday, August 7

Five things for pharma marketers to know: Friday, August 7

By

CVS excludes 31 drugs including Viagra from its 2016 formulary; Sanofi partners with Evotec on stem-cell treatment development; primary-care physicians may hesitate to prescribe Truvada for PrEP

Express Scripts' Steve Miller takes on drug industry in pricing battle

Express Scripts' Steve Miller takes on drug industry in pricing battle

By

The drug-pricing war between drugmakers and payers continues unabated. Dr. Steve Miller, Express Scripts' chief medical officer, talks about collaborating with pharma.